IP Library › Granted Patent US 10,738,126
Granted Patent B2
US 10,738,126 · App. 15/619,068 · Granted Aug 11, 2020

Anti-GITR antibodies and uses thereof

Inventors: Frank Delfino (Poughquag, NY); Dimitris Skokos (New York, NY); Bei Wang (Hastings-on-Hudson, NY)
Assignee: REGENERON PHARMACEUTICALS, INC.
C07K16/2878A61K39/39541A61K45/06C07K16/2803C07K16/2818A61K2039/507C07K2317/21C07K2317/33C07K2317/565C07K2317/75C07K2317/76C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,738,126
App. No.
15/619,068
Granted
Aug 11, 2020
Kind
B2
Abstract

Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced tumor necrosis factor receptor (GITR) and methods of using the same, including, e.g., methods of treatment using the same.

Claims (5)

1. An Isolated antibody or antigen-binding fragment thereof that binds glucocorticoid-induced tumor necrosis factor receptor (GITR), wherein the antibody or antigen-binding fragment thereof comprises a heavy chain complementarity determining region (HCDR)-1 comprising SEQ ID NO: 340, an HCDR2 comprising SEQ ID NO: 342, and an HCDR3 comprising SEQ ID NO: 344, and a light chain complementarity determining region (LCDR)-1 comprising SEQ ID NO: 404, an LCDR2 comprising SEQ ID NO: 406, and an LCDR3 comprising SEQ ID NO: 408.

2. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO: 338 and an LCVR having the amino acid sequence of SEQ ID NO: 402.

3. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 1 and a pharmaceutically acceptable carrier or diluent.

4. The antibody or antigen-binding fragment thereof of claim 1 , which is an antibody, comprising:

an HCDR-1 comprising SEQ ID NO: 340; an HCDR2 comprising SEQ ID NO: 342; an HCDR3 comprising SEQ ID NO: 344; an LCDR-1 comprising SEQ ID NO: 404; an LCDR2 comprising SEQ ID NO: 406; and an LCDR3 comprising SEQ ID NO: 408.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2017
From: DELFINO, FRANK; SKOKOS, DIMITRIS; WANG, BEI
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 044191/0303 →
Continuity (4)
Provisional Application 62348353 · Jun 10, 2016
Provisional Application 62432023 · Dec 9, 2016
Provisional Application 62500312 · May 2, 2017
Related Publication 20170355774A1 · Dec 14, 2017
Cited By (1)
US 12,331,127